Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – The deal announced in June in which Spain-based Grifols S.A. would acquire RTP-based Talecris Biotherapeutics (Nasdaq: TLCR) is under continuing review by the U.S. Federal Trade Commission.

Talecris said Monday that the FTC had requested more information from the companies.

Shares in Talecris traded at $22.25, down 4 cents, in late-afternoon trading.

Talecris filed information on July 6, and the “second request: is a “part of the regulatory process” as dictated by anti-trust legislation, the company said.

Grifols and Talecris agreed to a $4 billion in deal on June 7.

Talecris focuses on blood plasma-based therapeutics.

Get the latest news alerts: at Twitter.